USPTO serial 78705641
PARVULET
Reviewed by CopyMark Law Group
Reg. 4215867Status 710
- Filing date
- Status date
- Registration date
- Oct 2, 2012
- Examiner
- KEARNEY, COLLEEN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PARVULET?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
LONDON, GB
LAWRENCEVILLE, NJ
Kirke Værløse, DK
Kirke Værløse, DK
LONDON, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dianne M. Lambillotte
DAVID O. JOHANSON BINGHAM MCCUTCHEN LLPONE FEDERAL STREETBOSTON, MA 02110UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations for the treatment of pain relief and pain management, shock, hemorrhage and bleeding, pre- and post-operative complications in the nature of hemorrhage, bleeding, thrombosis, emboli, stroke, apoplexy, lesions, respiratory and circulatory crises and dysfunctions, cognitive dysfunctions, fibrosis, infections, fever and sepsis, and traumas and emergencies, namely, fractures, abrasions, burns, psychological and immunological shock, poisons and pollutions, animal bites or stings, fever, respiratory and cardiovascular shock, crises and dysfunctions, and hemorrhage, bleeding, thrombosis, emboli, stroke, apoplexy, lesions and cognitive dysfunctions, and physical and psychological substance dependence, namely, drug and alcohol dependence, drug tolerance, withdrawal symptoms, convulsions, Alzheimer disease, dementias, Parkinson's disease, insufficient saliva and inability to swallow, allergy/immunology disorders, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases in the nature of flu, AIDS/HIV, anthrax, plague, cholera, biological infections, and prion exposure, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, genitourinary diseases and afflictions, premature labor, poison exposure, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear, nose and throat, diseases and afflictions on the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions, veterinary preparations for the treatment of bovine, sheep, horses, pigs, poultry, ostrich, rodents, dogs, cats, camels, donkeys, elephants; dietetic food adapted for medical use; diagnostic preparations for medical and veterinary use; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; synthetic peptides for pharmaceutical purposes; vitamins; biomedical compounds, namely, peptide substrates for use in analyzing and detecting toxins for medical laboratory use; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets, oral liquids, oral gels, and oral emulsions for the continuous release of a wide variety of therapeutic agents within a certain time after ingestion; medicated candy; medicated chewing gum; breath-freshening chewing gum for medical purposes; medicated lollipops; sweets for medicinal purposes, namely, sweets containing pharmaceutical and medical substances and compounds | SECTION 8 - CANCELLED | — |
| 010 | Surgical, medical, dental and veterinary apparatus and instruments, namely, drug delivery apparatus and instruments in the form of containers for various pharmaceuticals, drugs, medicines, compounds and substances in the form of liquids, gels, grains, emulsions, blister packs and sachets; spoons, cups and syringes for administering pharmaceutical substances and medicines; drug delivery systems | SECTION 8 - CANCELLED | — |
| 040 | Treatment of materials, namely, milling, mixing, grinding, liquefying, pulverizing, melting and extrusion of medical and pharmaceutical substances, compounds and materials | SECTION 8 - CANCELLED | — |
| 042 | Scientific research; technology consultation in the field of scientific research; design for others in the fields of pain relief and pain management, pharmaceutical drug and medicine development, development of medicines and medicine goods and packaging in the fields of traumas and emergencies, addictions, aging, allergy/immunology, burns, diseases of the heart and blood vessels, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, epidemical diseases, diseases and afflictions of the gastroenterological system, diseases of the blood, infectious diseases, neurological diseases, nephrological diseases, diseases in the obstetrical- and gynecological field, occupational diseases and afflictions, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, diseases and afflictions of the ear-nose and throat, diseases and afflictions on the psychiatric field, pulmonological diseases and afflictions, rheumatism, urological diseases and afflictions, veterinary preparations for the treatment of bovine, sheep, horses, pigs, poultry, ostrich, rodents, dogs, cats, camels, donkeys, elephants; chemical, biochemical, biological and bacteriological research and analysis; pharmaceutical drug and medicine development services; design for others in the field of drugs and medicines; development of pharmaceutical preparations and medicines; professional consultancy pertaining to pharmacology, namely, biotechnical and biomedical and medical and pharmaceutical substances, preparations and compounds; professional consultancy in the field of research and development of medicine and the dispensing of pharmaceutical preparations; pharmaceutical drug development services comprised of scientific, industrial, technological, bio technical, pharmaceutical, biomedical and clinical research in the field of drugs and drug candidates; medical and scientific research, namely, conducting clinical trials of new drug candidates; consultation in the field of scientific research pertaining to chemical, pharmaceutical and medical goods; design for others in the field of medical packaging and equipment; development of pharmaceutical preparations and medicines; consultation in the field of biotechnological and biomedical scientific research; biochemical and molecular biological analyses; in vitro and in vivo preclinical tests and clinical tests of drug candidates and potential drugs; consultancy and research regarding pharmaceuticals in gel-like and viscous liquid dosage forms; consultancy and research pertaining to pharmacology in the nature of alternative drugs for the young, elderly and those with difficulties swallowing pills and tablets; development of in vitro and in vivo preclinical tests of drug candidates and potential drugs; biochemical and molecular biological analyses; scientific, industrial, technological and biotechnological analysis in the field of pharmaceutical and veterinary drug and medicine analysis, analysis of drug delivery apparatus and containers, analysis of synthetic peptides for pharmaceutical purposes, analysis of peptide substrates, analysis for the purpose of detecting various toxins, analysis of drug candidates and potential drugs | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by EGALET LTD
- Other trademarks owned by ADARE PHARMACEUTICALS, INC.
- Other trademarks owned by EGALET A/S
- Other trademarks owned by EGALET A/S
- Other trademarks owned by EGALET LTD
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named PARVULET
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 31, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| May 3, 2019 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Oct 2, 2017 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 14, 2016 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 14, 2016 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 2, 2012 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 29, 2012 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Aug 15, 2012 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Aug 15, 2012 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Feb 22, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 21, 2012 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Feb 10, 2012 | EXT5 | SOU EXTENSION 5 FILED | — |
| Feb 10, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 23, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 20, 2011 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 17, 2011 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 17, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 26, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 25, 2011 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 23, 2011 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 23, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 13, 2010 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 9, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 8, 2010 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 23, 2010 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 23, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 30, 2010 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 29, 2010 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 21, 2009 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 21, 2009 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 25, 2009 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 2, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 13, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| Apr 28, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 27, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 4, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 4, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 1, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 8, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 8, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 8, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 12, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 12, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 11, 2008 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 11, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 11, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 5, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 5, 2008 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 26, 2007 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 26, 2007 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 26, 2007 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 6, 2007 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 4, 2007 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| May 4, 2007 | ALIE | ASSIGNED TO LIE | — |
| Oct 25, 2006 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 25, 2006 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 3, 2006 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 3, 2006 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 2, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 2, 2006 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 30, 2006 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 16, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 27, 2006 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 15, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 15, 2006 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Sep 9, 2005 | NWAP | NEW APPLICATION ENTERED | — |